Nashwa Wahba, DO
Internal Medicine · Daytona Beach, FLNPI 1053753442
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 275 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by GSK at 24.5% of the total. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Jazz Pharmaceuticals Inc.$795
- Harmony Biosciences LLC$609
- AstraZeneca$469
- Sanofi$338
- Axsome Therapeutics, Inc.$234
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,49098%
- Education$1042%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 79 | $1,372 |
| Jazz Pharmaceuticals Inc. | 36 | $795 |
| Harmony Biosciences LLC | 22 | $609 |
| AstraZeneca | 27 | $469 |
| Sanofi | 14 | $338 |
| Axsome Therapeutics, Inc. | 12 | $234 |
| Boehringer Ingelheim | 11 | $216 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $202 |
| Regeneron Healthcare Solutions, Inc. | 9 | $202 |
| Grifols USA, LLC | 6 | $132 |
| Inspire Medical Systems, Inc. | 4 | $122 |
| Fisher & Paykel Healthcare Inc | 5 | $110 |
| Mylan Specialty L.p. | 4 | $93 |
| Sunovion Pharmaceuticals Inc. | 6 | $84 |
| Avadel CNS Pharmaceuticals, LLC | 4 | $82 |
| Shire North American Group Inc | 4 | $75 |
| Viatris Specialty LLC | 3 | $69 |
| Mallinckrodt Hospital Products Inc. | 3 | $64 |
| Philips North America LLC | 2 | $63 |
| Baxter Healthcare | 3 | $52 |
| Lilly USA, LLC | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| Electromed, Inc. | 1 | $21 |
| Merck | 1 | $20 |
| Circassia Inc. | 1 | $19 |
| Gilead | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $17 |
| 3b Medical, Inc. | 1 | $15 |
| Aytu Biopharma, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$5,595 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 143 | $126,315 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 65 | $73,566 |
| Breo ElliptaFluticasone/Vilanterol | 75 | $43,738 |
| SymbicortBudesonide/Formoterol Fumarate | 70 | $30,410 |
| Spiriva RespimatTiotropium Bromide | 25 | $23,577 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $10,995 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 51 | $8,369 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $7,996 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 193 | $7,770 |
| Modafinil | 87 | $5,799 |
| Advair DiskusFluticasone Propion/Salmeterol | 21 | $5,310 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $4,572 |
| Wixela InhubFluticasone Propion/Salmeterol | 31 | $3,526 |
| Ventolin HfaAlbuterol Sulfate | 33 | $2,388 |
| Zolpidem Tartrate | 217 | $2,296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,372 | $178,048229 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $469 | $103,975135 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $216 | $34,57344 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Daytona Beach
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.